CERS - Cerus signs new production & supply deal with Fresenius Kabi for INTERCEPT Blood System sets

Cerus (NASDAQ:CERS) on Tuesday signed a ten-year agreement with Germany's Fresenius Kabi for the production of INTERCEPT Blood System sets. Tuesday's new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025. Fresenius Kabi will continue producing sets for Cerus at its facility in La Châtre, France, and will also expand manufacturing operations to two new facilities located in the Caribbean. Cerus' INTERCEPT Blood System helps in reduction of pathogens in the blood and platelets and makes the blood safe for use in blood centers, hospitals and for patients. CERS stock +0.2% to $4.82 in early trading.

For further details see:

Cerus signs new production & supply deal with Fresenius Kabi for INTERCEPT Blood System sets